Daniel Hindley

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

U. Wieshmann, A. Chaudhuri, J. Gibb, 2021, The Lancet.